Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Prioderm®
malathion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ivermectin | EXPERIMENTAL | ivermectin Stromectol®) |
| Malathion | ACTIVE_COMPARATOR | malathion(Prioderm®) |
| Name | Type | Description |
|---|---|---|
| ivermectin | DRUG | Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion |
| malathion | DRUG | Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets |
Inclusion Criteria: * Head lice infestation confirmed by detection combing by study staff * previous (within 6 weeks) use of a topical insecticide product * minimum 15kg weight * providing informed consent Exclusion Criteria: * pregnant or nursing patients * households with 7 or more infested pat...
Malathion is a small molecule treatment for lice infestations. Johnson & Johnson has studied it in a Phase 3 clinical program for this infectious disease indication. It is applied as a topical therapy against head lice, a common parasitic condition affecting both children and adults.
Malathion is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company has sponsored a Phase 3 trial of the drug in lice infestations, evaluating its use in a pediatric and adult population across several countries.
Malathion is in Phase 3 development for lice infestations. The program includes one completed Phase 3 trial with 812 participants. No active trials are currently listed, and the drug remains investigational for this indication rather than approved.
Malathion has been evaluated in a single Phase 3 trial, NCT00819520, titled Ivermectin in the Treatment of Head Lice. The trial enrolled 812 participants, was randomized, double blind, and active controlled, and was conducted in France, Ireland, Israel, and the United Kingdom. It has completed.
Malathion is an investigational therapy in Phase 3 development for lice infestations. The completed Phase 3 trial, NCT00819520, evaluated the drug in 812 participants. No approval has been granted for this indication based on the available development data.